Orphan drugs compared: Switzerland, the European Union and the United States

The three legal bases

Each system rests on its own instrument. Switzerland works from Art. 4 para. 1 let. a decies TPA with Art. 4 to 7 and 24 to 26 TPLO. The European Union works from Regulation (EC) No 141/2000, with designation opinions from the EMA's Committee for Orphan Medicinal Products. The United States works from the Orphan Drug Act of 1983.

The three instruments were adopted decades apart, which explains much of the divergence. The Orphan Drug Act dates from 1983, Regulation (EC) No 141/2000 from 2000, and the Swiss provisions sit in the Therapeutic Products Act with implementation in the TPLO.

Side by side

The table below sets the three frameworks against each other on the points that change a development plan: the rarity threshold, whether a benefit argument is required, and what the designation is actually worth once granted. The differences in the last row are the ones most often misstated in Swiss planning documents.

The row on market exclusivity is the one to read twice. A development plan that assumes Swiss exclusivity because the EU grants ten years is built on a protection that does not exist in Switzerland at all.

Why the Swiss threshold behaves differently

Switzerland and the EU use the same numerical threshold of 5 in 10,000, but they ask for different things around it. Switzerland has no significant-benefit criterion, so an applicant does not have to argue superiority over existing therapies. The EU requires proof of significant benefit in addition to prevalence.

The Swiss rarity test is also applied to the disease in its entirety, including all of its stages. HER2-positive breast cancer does not qualify as a separate rare disease, and restricting an indication to second-line treatment does not create one either. A designation strategy built on subgroups does not transfer to Switzerland.

The absence of a significant-benefit test cuts both ways. It removes an argument the applicant would otherwise have to win, but it also means a Swiss status carries no implicit statement that the product is better than what already exists.

The exclusivity question

This is the single most consequential difference. Switzerland grants no market exclusivity for orphan drugs. What it offers instead is 15 years of document protection on request under Art. 11b para. 4 TPA, together with the simplified procedure, priority processing and the waiver of the flat-rate fee for the new authorisation application.

• EU: 10 years of market exclusivity, plus 2 years with a completed paediatric investigation plan.
• USA: 7 years of market exclusivity, plus tax credits and a fee waiver.
• Switzerland: no market exclusivity; 15 years of document protection on request under Art. 11b para. 4 TPA.

Document protection and market exclusivity are not interchangeable. Document protection restricts reliance on the originator documentation, while market exclusivity of the EU or US kind restricts the authorisation of similar products, and only the former exists in Switzerland.

The recognition route Switzerland offers and the others do not

Switzerland has a second entry point that has no equivalent in the EU or US systems. Orphan drug status can be granted because the product or its active substance is recognised as an important medicinal product for rare diseases in a country with equivalent medicinal product control under Art. 13 TPA, without a fresh Swiss prevalence argument.

1. Obtain the designation in a country with equivalent medicinal product control, for instance through the EU or US procedure.
2. Submit to Swissmedic all administrative and scientific documentation filed with that authority, plus a copy of the official designation decision and the assessment report where available.
3. Where several countries granted a designation, submit the decisions of all of them, with full documentation for the reference authority only.
4. Provide documentary evidence that the medicinal product or the active substance is identical.
5. Notify Swissmedic immediately of any change to the status abroad, under Art. 5 para. 2 TPLO.

The route saves the prevalence argument but not the documentation. Swissmedic expects the full file that went to the reference authority, so relying on a foreign designation is a matter of transferring a dossier rather than citing a decision.

What this means for a global development plan

Switzerland is rarely the bottleneck, but it is also not a copy of the EU procedure. The absence of a significant-benefit test lowers one hurdle, the whole-disease reading of the rarity criterion raises another, and the absence of market exclusivity changes the commercial calculation rather than the regulatory one.

• Plan the Swiss indication wording against the disease entity, not the EU subgroup wording.
• Use the Art. 13 TPA routes for both the status and the authorisation dossier where a foreign authorisation exists.
• Base commercial protection in Switzerland on document protection under Art. 11b para. 4 TPA, requested in time.
• Remember that the notification duty in Art. 5 para. 2 TPLO links the Swiss status to changes abroad.

Switzerland is best treated as a separate regulatory jurisdiction that happens to accept foreign work. The dossier can be reused extensively under Art. 13 TPA, but the indication wording, the status application and the reimbursement case have to be built for Switzerland.